

University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
April 14, 2026

Members attending the meeting: Bieniek, Kevin; Burgin, Tiffani; Chen, Ching-Kang Jason; Chen, Chun-Liang; Dell, Shelbie; Ginsburg, Brett; Gould, Georgianna; Kautz, Tiffany; Mishra, Bibhuti; Prewit, Egle; Shiio, Yuzuru; Vogel, Kristine; Wiederhold, Nathan; Xiang, Yan; Yeh, Chih-Ko; Bloodworth, Rebecca; Macias, Dorothy (alternate for Cerecero, Jennifer - voting)

Guests Present: Rincon, Erica; Melendez, Griselda.

Absent members: Cerecero, Jennifer; Chatterjee, Bandana; Gauduin, Marie Claire; Martinez-Sobrido, Luis; Paukert, Martin; Salamango, Daniel.

1. Panel Chair Announcement

The meeting was called to order at 11:00 a.m. by the IBC Chair, Dr. Yan Xiang.

2. Confidentiality of Panel Proceedings and Conflict of Interest

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. Approval of minutes from the previous meeting

The Committee approved the minutes as written from the March 17, 2026, IBC meeting.

Approved (17 voted to approve, 0 opposed, 0 abstained)

4. Review of Approved Protocols- The spreadsheet of approved protocols for FY2026 will be sent out for review in August 2026. As of April 1, 2026, 28 protocols had been approved by the full committee, and 26 had been approved administratively, for a total of 54 protocols to date.

5. Old Business –

6. Educational Items – None

7. Occupational Medicine- As of April 1, 2026, there were six cases of needlesticks, one case was by a UT staff member, and five cases were by UT students. There were five cases of bloodborne exposure: two

involving students and three involving UT staff members.

8. Other – None

9. Review of EHS Assistant-

Review any issues with the EH&S Assistant program.

10. Meeting Reminder

The next meeting will be held on May 12, 2026.

Protocols for Review

11. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000021704

Principal Investigator: Mustafa, Shamimunisa; Pediatrics-Neonatology

Title: N/A

Review Type: Full Committee Review

Form Type: Renewal

Approved (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with mesenchymal stem cells and primate blood/tissue at BSL-2 containment.
Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

12. Presentation, Discussion, and Voting on an Amendment Protocol:

Protocol ID: 0000021193

Principal Investigator: Zhu, Yi; Barshop Institute

Title: N/A

Review Type: Full Committee Review

Form Type: Amendment

Approved (17 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with AVV vectors (AAV-PHP-eB-GfaABC1D-dtomato, pAAV-GfaABC1D-tdTomato-P2A-NIL-Cre-WPR, pAAV-GfaABC1D-tdTomato-WPRE, pAAV-TIE1p-EGFP-P2A-NLS-Cre-WPRE, pAAV-TIE1p-MCS-EGFP-3XFLAG-WPR, pAAV-SM22ap-EGFP-P2A-NLS-Cre-WPRE, pAAV-SM22ap-MCS-EGFP-3XFLAG-WPRE, pAAV-CX3CRI-EGFP-3XFLAG-Wpre, pAAV-CX3CRI-NLS-Cre-P2A-EGFP-3XFLAG-WPRE) at BSL-2 containment.

In vivo:

Work with AAV vectors in knockout and transgenic mice at ABSL-2 containment.

IACUC# IPROTO202500000063

Protocol does include the use of recombinant DNA.

This protocol was approved with minor corrections.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4

Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

13. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000021707

Principal Investigator: O'Connor, Jason; Pharmacology

Title: N/A

Review Type: Full Committee Review

Form Type: Renewal

Approved (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with human post-mortem brain, human placental tissues/cells, human blood, human cell lines (THP-1, HL-60), and BCG at BSL-2 containment.

In vivo

Work with BCG in knockout and transgenic mice at ABSL-2 containment.

IACUC# 11009, 10121

Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:


Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1


Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

Adjourn: The meeting adjourned at 11:36 A.M.



Dr. Yan Xiang
Institutional Biosafety Committee Chair
University of Texas Health San Antonio



Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam